ANVS - Annovis Bio Inc logo

ANVS

Annovis Bio Inc

Annovis Bio develops drugs for neurodegenerative diseases, focusing on Alzheimer's and Parkinson's. Its lead candidate, Buntanetap, is in phase 3 trials, while ANVS405 targets traumatic brain injury and stroke in phase 2/3 programs.

⚕️ Healthcare NYSE Listed 2010 $ USD
$1,000 invested 5 years ago $43today

Score Overview

1 Year
Score
Net Growth-41.83%
Net TrendShrank
Net Income Consistency
Rev Growth
Rev TrendShrank
Revenue Consistency
5 Years
Score
Net Growth-182.48%
Net Trend20%
Net Income Consistency
Rev Growth
Rev TrendNever
Revenue Consistency
10 Years
Score
Net Growth-391.59%
Net Trend20%
Net Income Consistency
Rev Growth-100.00%
Rev TrendNever
Revenue Consistency
All Time
Score
Net Growth-29x
Net Trend17%
Net Income Consistency
Rev Growth-100.00%
Rev Trend8%
Revenue Consistency

See the full market ranking →

Annovis Bio Inc fundamental performance

Between 2011 and 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 4M to -$ 28M. Revenue increased in 0% of the years measured; net income in 20%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 1.80
1 Year2025-08-12
$ 2.77-35.02%
5 Years2021-08-12
$ 41.82-95.70%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 40M$ 14M
2025$ 0.00-$ 28M$ 19M
2024$ 0.00-$ 24M$ 10M
2023$ 0.00-$ 56M$ 5M
2022$ 0.00-$ 25M$ 28M
2021$ 0.00-$ 14M$ 45M
2020$ 0.00-$ 5M$ 8M
2019$ 0.00-$ 991K$ 1.86K
2018$ 0.00-$ 713.87K$ 35.31K
2017$ 0.00-$ 682.35K$ 347.47K
2012$ 185.18K-$ 8M
2011$ 0.00-$ 4M
IPO2010$ 7M-$ 1M

Explore beyond ANVS

You're looking at Annovis Bio Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies